Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 2/20 | 0.51 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621967 | 0.84 | NOTUM (0.67) | NOTUMMAPK1TP53MAPTTDP1 | |
| SCHEMBL5483599 | 0.83 | PTPN1 (0.69) | TDP1FAAHSCDSCD5ALDH1A1 | |
| SCHEMBL2960641 | 0.81 | NOTUM (0.62) | NOTUMMAPK1TP53MAPTTHRB | |
| SCHEMBL69157 | 0.80 | MAPT (0.72) | NOTUMMAPK1TP53MAPTLMNA | |
| SCHEMBL4051030 | 0.80 | NOTUM (0.60) | NOTUMMAPK1TP53MAPTTDP1 | |
| SCHEMBL1545189 | 0.80 | NOTUM (0.68) | NOTUMMAPK1TP53MAPTTHRB | |
| SCHEMBL5620616 | 0.80 | MAPT (0.72) | NOTUMMAPK1TP53MAPTTDP1 | |
| SCHEMBL22556944 | 0.78 | GRM5 (0.60) | ALDH1A1 | |
| SCHEMBL6288879 | 0.78 | USP30 (0.47) | MAPTTHRBLMNAALDH1A1 | |
| SCHEMBL18091774 | 0.77 | TP53 (0.60) | NOTUMMAPK1TP53MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007130824-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | NOTUM 2476/4885MAPK1 2272/4885TP53 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.